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Be Used to Predict Periprocedural
Myocardial Infarctions?*
Marc D. Feldman, MD,yz Jennifer E. Phipps, PHDyM ore than 1 million percutaneous coronaryinterventions (PCIs) are performed peryear in the United States. Although tech-
nological advances have signiﬁcantly improved out-
comes following PCI, 5% to 44% of PCI patients still
experience periprocedural myocardial infarction
(PMI). PMI can be either macro-sized (coronary
dissection or occlusion of a side branch) or microvas-
cular such as distal embolization and/or microvas-
cular plugging. PMIs have recently been deﬁned as
Type 4a: cardiac troponin (cTn) levels >5 elevation
above the 99th percentile upper reference limit
(URL), but only if the baseline cTn levels were normal
(#99th percentile URL) (1). In addition to the elevated
cTn levels, at least 1 of the following must be pre-
sent: 1) symptoms suggestive of myocardial ischemia;
2) new ischemic electrocardiographic (ECG) changes;
3) angiographic loss of patency of a coronary artery
or side branch; or 4) imaging demonstration of new
loss of viable myocardium or new regional wall mo-
tion abnormality (1). Despite the extensive literature
on this topic, most studies only utilize the enzyme
deﬁnition of type 4a infarction—rarely are angina,
ECG changes, and new wall motion abnormalities
taken into account. Although the universal deﬁni-
tion of type 4a myocardial infarction (MI) requires*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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disclose.elevation of cTn, the elevation of the biomarker cre-
atine phosphokinase myocardial band fraction (CPK-
MB) is felt by many clinicians to be a more speciﬁc
marker of PMI. Reﬂecting this view, a Society for
Cardiac Angiography and Interventions consensus
document recently proposed a more stringent deﬁ-
nition, based only on cardiac enzymes, of CPK-MB
>10 upper limit of normal (ULN) and cTn >70
ULN (2).
PMIs are associated with increased future mor-
tality. Whether PMI is simply a marker for more
extensive coronary artery disease or the actual
myocardial necrosis is accounting for the increased
mortality is unknown. In either case, it would be of
beneﬁt to identify these patients before PCI and
incorporate approaches during the intervention to
limit or prevent elevation of cTn and CPK-MB.
Approaches of proven beneﬁt include pre-treatment
with high-dose statin therapy and oral dual anti-
platelet therapy, and treatments during PCI including
distal protection devices, glycoprotein IIb/IIIa inhibi-
tion, and pre-conditioning.
Because it is the lipid-ﬁlled plaque that is respon-
sible for distal embolization with secondary platelet
activation and aggregation, one approach to pre-
identify these individuals is through the use of inva-
sive imaging techniques at the time of intervention
(3). These include attenuated plaques by gray-scale
intravascular ultrasound (IVUS), the necrotic core by
radiofrequency IVUS, the thin-capped ﬁbroatheroma
(TCFA) by optical coherence tomography (OCT), and
the large lipid core plaque by near-infrared spectros-
copy (NIRS). The search for which of these ap-
proaches will best predict PMI, including the use of
combinations of these approaches, is the goal of the
2 articles in this issue of JACC: Cardiovascular
Interventions (4,5).
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947Stone et al. (4) and Kini et al. (5) both used invasive
imaging endpoints that correlated with rates of PMI
following PCI. Both studies validated the previous
literature and found that the presence of large lipid
cores as identiﬁed by NIRS was associated with higher
levels of PMI. This ﬁnding, along with single-center
data demonstrating the association of NIRS-
identiﬁed lipid with material captured in ﬁlter de-
vices (6), was the basis for the CANARY (Coronary
Assessment by Near-infrared of Atherosclerotic
Rupture-prone Yellow) trial. The hope was that
despite the negative previous literature related to the
use of distal protection devices in native coronary
arteries, invasive imaging would provide a rebirth of
distal protection in this patient subset. Despite these
high hopes, the CANARY trial was negative. The
impact of more than one-half of PMIs arising from
lesions with a maximum lipid-core burden index in
4 mm (maxLCBI4mm) #600, and 57% of target lesions
having side branches that could not be protected by
the ﬁlter wire both mitigated against a positive
ﬁnding for this study.SEE PAGES 927 AND 937The limitation of NIRS is that it does not provide
axial resolution, that is, the depth of lipid cannot be
determined. Thus, a small superﬁcial lipid pool may
have a similar appearance to a large, deep lipid pool.
However, a large, deep lipid pool is less likely to
embolize during intervention. That may explain the
inability of NIRS to consistently predict PMI. For
instance, a maxLCBI4mm $500 only predicted 50% of
PMI (7 of 14 patients) in a previous study (7), and
maxLCBI4mm $600 only predicted 29% (9 of 31 pa-
tients) in Stone et al. (4). The Kini et al. (5) study
found that maxLCBI4mm $500 predicted 80% of
PMI (8 of 10 patients), but by multivariant analysis,OCT-determined ﬁbrous cap thickness was the only
independent predictor for cTn elevations >3 ULN.
Although Kini et al. (5) are the ﬁrst to demonstrate
the superiority of OCT-deﬁned TCFA compared with
other imaging modalities, other investigators have
previously demonstrated the strong association be-
tween OCT TCFA and PMI. Lee et al. (8) demonstrated
TCFA to be the strongest independent predictor of
PMI. The magnitude and consistency of association of
OCT TCFA and adverse outcomes post-intervention
were also supported by 2 subsequent studies (9,10).
We have reviewed the more than 1,600 studies that
have been published regarding coronary OCT,
particularly the 40 that examined OCT-deﬁned TCFA.
Eight of these studies tabulated the frequency per
coronary artery length of the presence of TCFA. An
average of 0.99  1.14 OCT TCFA per 10 cm of coro-
nary artery was tabulated (11–18). With this high fre-
quency, the next step in invasive imaging to predict
and prevent PMI would be a trial comparing patients
with the presence of OCT TCFA in the vessel under-
going intervention randomized to either distal pro-
tection or antiplatelet medications versus control.
Finally, it would be ideal for future studies to use the
universal deﬁnition of type 4a MI (1) that includes
angina and/or ECG changes—both studies reviewed
here identiﬁed patients with PMI by cTn elevation
>3 the URL. Likely, the more stringent inclusion
criteria would limit the number of patients enrolled in
these studies but could improve the accuracy of the
results.
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